Protalex, Inc. (PRTX) Receives Third Interim Review from Independent Data Safety Monitoring Committee in its Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis
7/23/2013 9:34:18 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its Independent Data Safety Monitoring Committee (SMC), the Company is continuing enrollment in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA). PRTX-100 is a candidate drug incorporating a highly-purified form of Staphylococcal Protein A.
Help employers find you! Check out all the jobs and post your resume.
comments powered by